癌症免疫治療市場規模- 分產品（單株抗體、癌症疫苗、免疫調節劑、溶瘤病毒療法、細胞激素）、癌症類型（肺癌、乳癌、大腸癌、攝護腺癌、胰臟癌）、最終用途和預測，2024 - 2032 年

由於癌症發生率不斷上升，2024 年至 2032 年間，全球癌症免疫治療市場的複合年成長率將超過 9.3%，從而增強了對先進有效治療方案的需求。

免疫療法利用人體的免疫系統來瞄準並摧毀癌細胞，為傳統療法提供了一個有前景的替代方案。生物技術和分子醫學的進步促進了創新免疫療法藥物的開發，與傳統治療方法相比，這些藥物具有更高的療效和更少的副作用。此外，製藥公司對研發的大量投資和有利的監管政策正在加速新免疫療法產品的批准和商業化。例如，2024年6月，FDA批准默沙東的KEYTRUDA(R) pembrolizumab合併卡鉑和紫杉醇治療晚期或復發性子宮內膜癌。

癌症免疫治療市場根據產品、癌症類型、最終用途和地區進行細分。

由於對個人化醫療的日益重視以及對能夠有效調節免疫系統的療法的需求，免疫調節劑領域將在 2032 年呈現出值得注意的複合年成長率。免疫調節劑可增強人體對癌症的天然防禦能力，進而產生更量身訂做且可能有效的治療方案。此外，隨著研究揭示癌症與免疫系統之間複雜的相互作用，人們更加關注開發專門針對這些機制的療法。這種不斷成長的理解以及對更精確和適應性治療的追求猛增了對免疫調節劑的需求。

受未滿足的醫療需求和疾病的複雜性的推動，到 2032 年，肺癌領域將佔據前景廣闊的癌症免疫治療市場佔有率。肺癌死亡率高且亞型多樣，對有效治療提出了重大挑戰。免疫療法透過針對特定癌細胞並有可能改善患者的治療結果，提供了一種有前景的替代方案。針對肺癌創新治療的持續研發工作將推動該領域的成長。

北美癌症免疫治療市場在預測期內將呈現出有希望的複合年成長率。先進的醫療基礎設施和高水準的研究經費促進了新療法的快速開發和採用。該地區成熟的製藥和生物技術產業有助於快速創新和監管批准。此外，公共和私人對癌症研究的投資不斷增加，加上癌症發生率的上升，增加了對有效治療的需求。對個人化醫療和患者獲得現代療法的高度重視將刺激整個地區採用免疫療法解決方案。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 癌症盛行率上升
    • 研究與開發的進步
    • 個性化醫療和生物標誌開發
  • 產業陷阱與挑戰
    • 治療費用高
    • 與治療相關的副作用風險
• 成長潛力分析
• 技術景觀
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 單株抗體
• 癌症疫苗
• 免疫調節劑
  • 檢查點抑制劑
  • 免疫檢查點調節劑
  • 其他免疫調節劑
• 細胞因子
• 溶瘤病毒療法

第 6 章：市場估計與預測：按癌症類型，2021 - 2032 年

• 主要趨勢
• 肺癌
• 乳癌
• 大腸直腸癌
• 黑色素瘤
• 攝護腺癌
• 胰腺癌
• 其他癌症類型

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院
• 專科診所
• 癌症研究中心

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Celldex Therapeutics, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GSK plc
• Immunocore Holdings plc
• Johnson & Johnson
• Merck & Co., Inc
• Novartis AG
• Pfizer Inc.

Global Cancer Immunotherapy Market will witness over 9.3% CAGR between 2024 and 2032, catapulted by the escalating cancer incidence, bolstering the demand for advanced and effective treatment options.

Immunotherapy, which harnesses the body's immune system to target and destroy cancer cells, offers a promising alternative to traditional treatments. Advancements in biotechnology and molecular medicine have led to the development of innovative immunotherapy drugs that offer improved efficacy and fewer side effects compared to traditional treatments. Additionally, substantial investments in R&D by pharmaceutical companies and favorable regulatory policies are accelerating the approval and commercialization of new immunotherapy products. For instance, in June 2024, the FDA approved Merck's KEYTRUDA(R) pembrolizumab combined with carboplatin and paclitaxel as treatment for advanced or recurrent endometrial carcinoma.

The cancer immunotherapy market is segmented based on product, cancer type, end-use, and region.

The immunomodulators segment will showcase a noteworthy CAGR through 2032, due to a growing emphasis on personalized medicine and the need for therapies that can modulate the immune system effectively. Immunomodulators enhance the body's natural defenses against cancer, leading to more tailored and potentially effective treatment options. Additionally, as research reveals the complex interactions between cancer and the immune system, there is a heightened focus on developing therapies that can specifically target these mechanisms. This growing understanding and the quest for more precise and adaptive treatments catapult the demand for immunomodulators.

The lung cancer segment will hold a promising cancer immunotherapy market share by 2032, driven by the high unmet medical need and the complex nature of the disease. Lung cancer, with its high mortality rate and diverse subtypes, presents significant challenges for effective treatment. Immunotherapy offers a promising alternative by targeting specific cancer cells and potentially improving patient outcomes. The continued R&D efforts aimed at innovative treatments for lung cancer will drive the segment growth.

North America cancer immunotherapy market will exhibit a promising CAGR during the forecast period. Advanced healthcare infrastructure and high levels of research funding facilitate rapid development and adoption of new therapies. The regions well-established pharmaceutical and biotech industries contribute to swift innovation and regulatory approvals. Additionally, increasing public and private investments in cancer research, coupled with a rising prevalence of cancer cases, heighten the demand for effective treatments. The strong emphasis on personalized medicine and patient access to modern therapies will spur the adoption of immunotherapy solutions across the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cancer
    • 3.2.1.2 Advancements in research and development
    • 3.2.1.3 Personalized medicine and biomarker development
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Risk of side effects associated with the treatment
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Monoclonal antibodies
• 5.3 Cancer vaccines
• 5.4 Immunomodulators
  • 5.4.1 Checkpoint inhibitors
  • 5.4.2 Immune checkpoint modulators
  • 5.4.3 Other immunomodulators
• 5.5 Cytokines
• 5.6 Oncolytic viral therapies

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Lung cancer
• 6.3 Breast cancer
• 6.4 Colorectal cancer
• 6.5 Melanoma
• 6.6 Prostate cancer
• 6.7 Pancreatic cancer
• 6.8 Other cancer types

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Cancer research centers

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 AstraZeneca PLC
• 9.4 Bayer AG
• 9.5 Bristol-Myers Squibb Company
• 9.6 Celldex Therapeutics, Inc.
• 9.7 Eli Lilly and Company
• 9.8 F. Hoffmann-La Roche Ltd.
• 9.9 Gilead Sciences, Inc.
• 9.10 GSK plc
• 9.11 Immunocore Holdings plc
• 9.12 Johnson & Johnson
• 9.13 Merck & Co., Inc
• 9.14 Novartis AG
• 9.15 Pfizer Inc.